| 000 | 01595 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518023217.0 | ||
| 264 | 0 | _c20200713 | |
| 008 | 202007s 0 0 eng d | ||
| 022 | _a2160-7648 | ||
| 024 | 7 |
_a10.1002/cpdd.662 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShen, Zancong | |
| 245 | 0 | 0 |
_aLesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers. _h[electronic resource] |
| 260 |
_bClinical pharmacology in drug development _c07 2019 |
||
| 300 |
_a657-663 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnticoagulants _xblood |
| 650 | 0 | 4 |
_aBlood Coagulation _xdrug effects |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2C9 _xgenetics |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aGout Suppressants _xpharmacology |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProthrombin Time |
| 650 | 0 | 4 |
_aThioglycolates _xpharmacology |
| 650 | 0 | 4 |
_aTriazoles _xpharmacology |
| 650 | 0 | 4 |
_aVitamin K Epoxide Reductases _xgenetics |
| 650 | 0 | 4 |
_aWarfarin _xblood |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aLee, Caroline A | |
| 700 | 1 | _aWallach, Kathleen | |
| 700 | 1 | _aValdez, Shakti | |
| 700 | 1 | _aWilson, David M | |
| 700 | 1 | _aKerr, Bradley | |
| 700 | 1 | _aGillen, Michael | |
| 773 | 0 |
_tClinical pharmacology in drug development _gvol. 8 _gno. 5 _gp. 657-663 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpdd.662 _zAvailable from publisher's website |
| 999 |
_c29367491 _d29367491 |
||